17772-132 : Qelbree 150 mg Oral Capsule, Extended Release
NDC: | 17772-132 |
Labeler: | Supernus Pharmaceuticals, Inc |
Product Type: | Human Prescription Drug |
Drug Name: | Qelbree |
Dosage Form: | Oral Capsule, Extended Release |
Application #: | NDA211964 |
Rev. Date: |
NDC Package Codes:
- 17772-132-01: 100 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (17772‑132‑01)
- 17772-132-07: 7 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (17772‑132‑07)
- 17772-132-30: 30 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (17772‑132‑30)
- 17772-132-60: 60 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (17772‑132‑60)
- 17772-132-90: 90 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (17772‑132‑90)
Active Ingredients:
- Viloxazine Hydrochloride
Dosage Strength:
- 150 mg
Pharmaceutical Classes:
- Cytochrome P450 1A2 Inhibitors [MoA]
- Cytochrome P450 2B6 Inhibitors [MoA]
- Cytochrome P450 2D6 Inhibitors [MoA]
- Cytochrome P450 3A4 Inhibitors [MoA]
- Norepinephrine Reuptake Inhibitor [EPC]
- Norepinephrine Uptake Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 17772-131 Qelbree 100 mg Oral Capsule, Extended Release by Supernus Pharmaceuticals, Inc
- 17772-133 Qelbree 200 mg Oral Capsule, Extended Release by Supernus Pharmaceuticals, Inc
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 17772-131Next: 17772-133 >
Related Discussions:
Quelbree (Viloxazine) vs Strattera (Atomoxetine)
Quelbree (Viloxazine) vs Strattera (Atomoxetine) Has anyone tried both who can compare them? ## I spelled Qelbree wrong.... 1 reply
Quelbree (Viloxazine) vs Strattera (Atomoxetine) Has anyone tried both who can compare them? ## I spelled Qelbree wrong.... 1 reply
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.